Moving towards a new class of vaccines for non-infectious chronic diseases

Chackerian, Bryce; Frietze, Kathryn M.

doi:10.1586/14760584.2016.1159136

Cited by 22 publications

(30 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antigenic determinants multiply repeatedly on the VLP surface and promote complement fixation and B-lymphocyte receptor clusterization leading to the activation of the immune response. Additionally, the same antigen multiply displayed on the surface of the particle promotes the multiplication of the pool of autoreactive B-cells, which is the primary objective when designing vaccines against autoimmune diseases and tumors [29].…”

Section: Peptides As Protective Antigensmentioning

confidence: 99%

“…In most cases, VLPs assembled from a virus protein are considered as a candidate vaccine against this very virus, since protein monomers in multimeric configuration (VLP) induce a more potent immune response than protein monomers [29,30]. The strong immunogenic properties of VLPs are determined by several factors.…”

Section: Natural Sources For Vlp Bioengineering and The Specificmentioning

confidence: 99%

See 1 more Smart Citation

Virus-Like Particles as an Instrument of Vaccine Production

Syomin

Ilyin

2019

Mol Biol

View full text Add to dashboard Cite

The paper discusses the techniques which are currently implemented for vaccine production based on virus-like particles (VLPs). The factors which determine the characteristics of VLP monomers assembly are provided in detail. Analysis of the literature demonstrates that the development of the techniques of VLP production and immobilization of target antigens on their surface have led to the development of universal platforms which make it possible for virtually any known antigen to be exposed on the particle surface in a highly concentrated form. As a result, the focus of attention has shifted from the approaches to VLP production to the development of a precise interface between the organism's immune system and the peptides inducing a strong immune response to pathogens or the organism's own pathological cells. Immunome-specified methods for vaccine design and the prospects of immunoprophylaxis are discussed. Certain examples of vaccines against viral diseases and cancers are considered.

show abstract

Section: Peptides As Protective Antigensmentioning

confidence: 99%

Section: Natural Sources For Vlp Bioengineering and The Specificmentioning

confidence: 99%

Virus-Like Particles as an Instrument of Vaccine Production

Syomin

Ilyin

2019

Mol Biol

View full text Add to dashboard Cite

show abstract

“…Reports to date have shown that auto-antibodies typically have short half-lives between three months and one year without a booster vaccination [65,66]. This means that repeated injection of active immunotherapy agents is required to maintain immunity, and it presents the possibility that simply discontinuing boosting may be sufficient to halt treatment.…”

Section: Low Complexity: Single Cytokine Interventionsmentioning

confidence: 99%

Biomaterial strategies for generating therapeutic immune responses

Kelly

Shores

Votaw

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Biomaterials employed to raise therapeutic immune responses have become a complex and active field. Historically, vaccines have been developed primarily to fight infectious diseases, but recent years have seen the development of immunologically active biomaterials towards an expanding list of non-infectious diseases and conditions including inflammation, autoimmunity, wounds, cancer, and others. This review structures its discussion of these approaches around a progression from single-target strategies to those that engage increasingly complex and multifactorial immune responses. First the targeting of specific individual cytokines is discussed, both in terms of delivering the cytokines or blocking agents, and in terms of active immunotherapies that raise neutralizing immune responses against such single cytokine targets. Next, non-biological complex drugs such as randomized polyamino acid copolymers are discussed in terms of their ability to raise multiple different therapeutic immune responses, particularly in the context of autoimmunity. Last, biologically derived matrices and materials are discussed in terms of their ability to raise complex immune responses in the context of tissue repair. Collectively, these examples reflect the tremendous diversity of existing approaches and the breadth of opportunities that remain for generating therapeutic immune responses using biomaterials.

show abstract

“…We recommend a recent review on novel vaccines constructed on RNA phage VLPs [237] as well as special reviews on vaccines against allergies [238,239,240], Alzheimer disease [241], hypertension [242,243,244], influenza [245,246], malaria [247], and nicotine addiction [248,249,250,251,252]. …”

Section: Vaccines and Vaccine Candidatesmentioning

confidence: 99%

The True Story and Advantages of RNA Phage Capsids as Nanotools

et al. 2016

View full text Add to dashboard Cite

RNA phages are often used as prototypes for modern recombinant virus-like particle (VLP) technologies. Icosahedral RNA phage VLPs can be formed from coat proteins (CPs) and are efficiently produced in bacteria and yeast. Both genetic fusion and chemical coupling have been successfully used for the production of numerous chimeras based on RNA phage VLPs. In this review, we describe advances in RNA phage VLP technology along with the history of the Leviviridae family, including its taxonomical organization, genomic structure, and important role in the development of molecular biology. Comparative 3D structures of different RNA phage VLPs are used to explain the level of VLP tolerance to foreign elements displayed on VLP surfaces. We also summarize data that demonstrate the ability of CPs to tolerate different organic (peptides, oligonucleotides, and carbohydrates) and inorganic (metal ions) compounds either chemically coupled or noncovalently added to the outer and/or inner surfaces of VLPs. Finally, we present lists of nanotechnological RNA phage VLP applications, such as experimental vaccines constructed by genetic fusion and chemical coupling methodologies, nanocontainers for targeted drug delivery, and bioimaging tools.

show abstract

Moving towards a new class of vaccines for non-infectious chronic diseases

Cited by 22 publications

References 19 publications

Virus-Like Particles as an Instrument of Vaccine Production

Virus-Like Particles as an Instrument of Vaccine Production

Biomaterial strategies for generating therapeutic immune responses

The True Story and Advantages of RNA Phage Capsids as Nanotools

Contact Info

Product

Resources

About